Shaping the future of treatment decision making using Multigene Assays(MGA): An expert round table discussion
Focus on the Pre-Operative Genomic Testing was one of the Key Messages from the Exact Sciences Symposium at St. Gallen 2025. The session also included expert contributions from key opinion leaders where topics like systemic treatment decision-making, neoadjuvant strategies, and patient engagement were shared.
19th St. Gallen International Breast Cancer Conference
Key Messages from the Exact Sciences Symposium
Professor Shani Paluch-Shimon: Optimizing systemic treatment choices using the Oncotype DX BreastRecurrence Score Result pre-operatively
Professor, Stephen Chia MD, FRCP(C): Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DXBreast Recurrence Score Result
Mr Henry Cain: Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?
Patient perspectives: A round table discussion with Prof. Stephen Chia, Prof. Shani Paluch Shimon, and Mr Henry Cain
Events based video library
EBCC 2024 Satellite symposium recording
[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!
Evolving clinical practice for multi-gene assays: what’s new![EBCC24] Implications of updated guidelines for MGAs: Introduction
Implications of updated guidelines for MGAs: Introduction[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient
Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.[EBCC24] Challenging cases: N1 – premenopausal
Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help...ESMO 2024 Satellite symposium recording
[ESMO24] Insights from ESMO24 - Exact Sciences Educational Symposium
Tools to Guide Treatment Decisions in Early Breast Cancer: Genomic Testing and Emerging Role of MRD[ESMO24] Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.[ESMO24] Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.[ESMO24] Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.[ESMO24] Optimizing the approach to MRD assay development
Rick Baehner provides a topline overview of ongoing research into the development of MRD assays.MDT Live Video Series
MDT Live October 2024
MDT Live March 2024
Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases.[MDT Live March 2024] Case 1 Premenopausal Node Negative Patient
[MDT Live March 2024] Case 2 Older Node Positive Patient
[MDT Live March 2024] Case 3 Postmenopausal N1 Patient
[MDT Live March 2024] Case 4 Postmenopausal Lobular Patient
[MDT Live March 2024] Case 5 Premenopausal Tubular Patient
[MDT Live March 2024] Case 6 Premenopausal T3 Patient
[MDT Live March 2024] Case 7 Male Breast Cancer Patient
[MDT Live March 2024] Case 8 Postmenopausal Node Positive Patient
[MDT Live March 2024] Case 9 Postmenopausal Node-Negative Patient
[MDT Live March 2024] Q&A and Close
Other webinar and event recordings
St Gallen 2024 - Improve patient care with genomic testing
Patient's awareness and understanding of genomic testing - Professor Richard Simcock, UK
St Gallen 2024 - Improve patient care with genomic testing
Identifying patients for Oncotype DX® testing in my clinical practice - Professor Christos Markopoulos, Greece
The Oncotype DX® Test: Evolution of UK Real World Outcomes Data
Miss Marianne Dillon, Consultant Oncoplastic Breast Surgeon from Swansea Bay University Health Board, Dr Wendy Taylor Consultant Clinical Oncologist...
Follow the evidence to help guide chemotherapy decisions for early breast cancer patients
Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director
Clinical utility of multigene assays in early breast cancer: Predictive tests
A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay...
Landmark RxPONDER Trial results presented at the 2020 SABCS
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0-25.
Get in touch
Have questions about Oncotype DX®?
